靶向血液系统恶性肿瘤中的 microRNA。
Targeting microRNA in hematologic malignancies.
机构信息
Division of Dermatology.
Beckman Research Institute, City of Hope, Duarte, California, USA.
出版信息
Curr Opin Oncol. 2020 Sep;32(5):535-544. doi: 10.1097/CCO.0000000000000657.
Abstract
PURPOSE OF REVIEW
MiRNAs are critical regulators for gene expression. Numerous studies have revealed how miRNAs contribute to the pathogenesis of hematologic malignancies.
RECENT FINDINGS
The identification of novel miRNA regulatory factors and pathways crucial for miRNA dysregulation has been linked to hematologic malignancies. miRNA expression profiling has shown their potential to predict outcomes and treatment responses. Recently, targeting miRNA biogenesis or pathways has become a promising therapeutic strategy with recent miRNA-therapeutics being developed.
SUMMARY
We provide a comprehensive overview of the role of miRNAs for diagnosis, prognosis, and therapeutic potential in hematologic malignancies.
摘要
目的综述
miRNAs 是基因表达的关键调节因子。大量研究揭示了 miRNAs 如何导致血液系统恶性肿瘤的发病机制。
最近的发现
鉴定新的 miRNA 调控因子和途径对于 miRNA 失调至关重要，与血液系统恶性肿瘤有关。miRNA 表达谱分析表明其具有预测结局和治疗反应的潜力。最近，靶向 miRNA 生物发生或途径已成为一种有前途的治疗策略，最近正在开发 miRNA 治疗药物。
总结
我们全面概述了 miRNAs 在血液系统恶性肿瘤中的诊断、预后和治疗潜力。
相似文献
1
Targeting microRNA in hematologic malignancies.
Curr Opin Oncol. 2020 Sep;32(5):535-544. doi: 10.1097/CCO.0000000000000657.
2
Role of microRNAs in hematological malignancies.
Expert Rev Hematol. 2009 Aug;2(4):415-23. doi: 10.1586/ehm.09.32.
3
MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies.
Crit Rev Oncol Hematol. 2015 Jan;93(1):1-17. doi: 10.1016/j.critrevonc.2014.08.006. Epub 2014 Sep 2.
4
MicroRNA expression and function in cancer.
Trends Mol Med. 2006 Dec;12(12):580-7. doi: 10.1016/j.molmed.2006.10.006. Epub 2006 Oct 30.
5
MicroRNAs in hematological malignancies.
Blood Rev. 2013 May;27(3):143-54. doi: 10.1016/j.blre.2013.04.002. Epub 2013 Apr 25.
6
Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies.
Expert Rev Mol Diagn. 2012 Sep;12(7):755-65. doi: 10.1586/erm.12.64.
7
Steroid receptor and microRNA regulation in cancer.
Curr Opin Oncol. 2010 Nov;22(6):592-7. doi: 10.1097/CCO.0b013e32833ea80c.
8
The role of microRNAs in the pathogenesis and treatment of hematopoietic malignancies.
Curr Pharm Des. 2013;19(7):1201-10. doi: 10.2174/138161213804805649.
9
Emerging role of let-7 family in the pathogenesis of hematological malignancies.
Biomed Pharmacother. 2021 Dec;144:112334. doi: 10.1016/j.biopha.2021.112334. Epub 2021 Oct 13.
10
MicroRNAs in hematological malignancies: a novel approach to targeted therapy.
Hematology. 2012 May;17(3):170-5. doi: 10.1179/102453312X13376952196656.
引用本文的文献
1
MicroRNA Signatures: Illuminating Minimal Residual Disease Monitoring in Juvenile Myelomonocytic Leukemia - A Review.
J Hematol. 2025 Apr;14(2):43-55. doi: 10.14740/jh1384. Epub 2025 Apr 25.
2
The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies: A Central Study.
Biomolecules. 2024 Dec 7;14(12):1559. doi: 10.3390/biom14121559.
3
Clinical implications of miRNAs in erythropoiesis, anemia, and other hematological disorders.
Mol Biol Rep. 2024 Oct 18;51(1):1064. doi: 10.1007/s11033-024-09981-w.
4
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia.
Sci Rep. 2024 Jul 2;14(1):15089. doi: 10.1038/s41598-024-65404-7.
5
Dysregulation of Non-Coding RNAs: Roles of miRNAs and lncRNAs in the Pathogenesis of Multiple Myeloma.
Noncoding RNA. 2023 Nov 3;9(6):68. doi: 10.3390/ncrna9060068.
6
Clinical Significance of microRNAs in Hematologic Malignancies and Hematopoietic Stem Cell Transplantation.
Cancers (Basel). 2023 May 8;15(9):2658. doi: 10.3390/cancers15092658.
7
Advances in the application of Raman spectroscopy in haematological tumours.
Front Bioeng Biotechnol. 2023 Jan 10;10:1103785. doi: 10.3389/fbioe.2022.1103785. eCollection 2022.
8
Role of microRNAs in B-Cell Compartment: Development, Proliferation and Hematological Diseases.
Biomedicines. 2022 Aug 18;10(8):2004. doi: 10.3390/biomedicines10082004.
9
Identification of uPAR Variants Acting as ceRNAs in Leukaemia Cells.
Cancers (Basel). 2022 Apr 14;14(8):1980. doi: 10.3390/cancers14081980.
10
One Omics Approach Does Not Rule Them All: The Metabolome and the Epigenome Join Forces in Haematological Malignancies.
Epigenomes. 2021 Oct 8;5(4):22. doi: 10.3390/epigenomes5040022.
本文引用的文献
1
MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Leuk Res. 2020 Feb;89:106296. doi: 10.1016/j.leukres.2020.106296. Epub 2020 Jan 3.
2
The emerging role of microRNAs in the molecular diagnosis of mycosis fungoides.
Br J Dermatol. 2019 May;180(5):984-985. doi: 10.1111/bjd.17768.
3
Differential expression of miRNAs in acute myeloid leukemia quantified by Nextgen sequencing of whole blood samples.
PLoS One. 2019 Mar 20;14(3):e0213078. doi: 10.1371/journal.pone.0213078. eCollection 2019.
4
Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
J Invest Dermatol. 2019 Sep;139(9):1966-1974.e3. doi: 10.1016/j.jid.2019.01.033. Epub 2019 Mar 12.
5
Publisher Correction: Regulation of microRNA biogenesis and its crosstalk with other cellular pathways.
Nat Rev Mol Cell Biol. 2019 May;20(5):321. doi: 10.1038/s41580-019-0106-6.
6
Abnormal microRNA expression in the course of hematological malignancies.
Cancer Manag Res. 2018 Oct 8;10:4267-4277. doi: 10.2147/CMAR.S174476. eCollection 2018.
7
Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma.
Br J Haematol. 2018 Nov;183(3):428-444. doi: 10.1111/bjh.15547. Epub 2018 Aug 20.
8
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.
Front Endocrinol (Lausanne). 2018 Aug 3;9:402. doi: 10.3389/fendo.2018.00402. eCollection 2018.
9
miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling.
Nat Commun. 2018 Jun 20;9(1):2418. doi: 10.1038/s41467-018-04831-3.
10
The impact of Mir-9 regulation in normal and malignant hematopoiesis.
Oncol Rev. 2018 Mar 27;12(1):348. doi: 10.4081/oncol.2018.348. eCollection 2018 Jan 30.
Zotero 插件